ArticleMolecular and cellular biology2003
Of mice and MEN1: Insulinomas in a conditional mouse knockout.
Article in Molecular and cellular biology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 247 citations in OpenAlex.
- Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1.Journal of neuroendocrinology · 2026Article
- Integrated proteomic analysis identifies TYMS-dependent AMPK-mTOR signaling in pancreatic neuroendocrine tumors.iScience · 2025Article
- A neural substrate of comorbid depressive symptoms in alcohol use.Molecular psychiatry · 2025Article
- Article
- Menin Reduces Parvalbumin Expression and is Required for the Anti-Depressant Function of Ketamine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Alternative splicing generates isoform diversity inEndocrine oncology (Bristol, England) · 2024Article
- NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations.Endocrine oncology (Bristol, England) · 2024Review
- Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.The Journal of clinical endocrinology and metabolism · 2023Article
- Molecular and Clinical Spectrum of Primary Hyperparathyroidism.Endocrine reviews · 2023Article
- Metabolic intervention by low carbohydrate diet suppresses the onset and progression of neuroendocrine tumors.Cell death & disease · 2023Article
- Hypothalamic Menin regulates systemic aging and cognitive decline.PLoS biology · 2023Article
- Selective Menin Deletion in the Hippocampal CA1 Region Leads to Disruption of Contextual Memory in theCells · 2022Article
- Preclinical Models of Neuroendocrine Neoplasia.Cancers · 2022Review
- miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.International journal of molecular sciences · 2022Review
- Mice With RIP-Cre-mediated Deletion of the Long Noncoding RNAJournal of the Endocrine Society · 2022Article
- Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival.JCI insight · 2022Article
- Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin.Cells · 2022Article
- Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.Disease models & mechanisms · 2022Article
- Review
- A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.The Journal of clinical endocrinology and metabolism · 2021Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
Abstract
Patients with multiple endocrine neoplasia type 1 (MEN1) develop multiple endocrine tumors, primarily affecting the parathyroid, pituitary, and endocrine pancreas, due to the inactivation of the MEN1 gene. A conditional mouse model was developed to evaluate the loss of the mouse homolog, Men1, in the pancreatic beta cell. Men1 in these mice contains exons 3 to 8 flanked by loxP sites, such that, when the mice are crossed to transgenic mice expressing cre from the rat insulin promoter (RIP-cre), exons 3 to 8 are deleted in beta cells. By 60 weeks of age, >80% of mice homozygous for the floxed Men1 gene and expressing RIP-cre develop multiple pancreatic islet adenomas. The formation of adenomas results in elevated serum insulin levels and decreased blood glucose levels. The delay in tumor appearance, even with early loss of both copies of Men1, implies that additional somatic events are required for adenoma formation in beta cells. Comparative genomic hybridization of beta cell tumor DNA from these mice reveals duplication of chromosome 11, potentially revealing regions of interest with respect to tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.